Cargando…

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease

BACKGROUND: Inadequate infliximab (IFX) drug exposure remains a clinical challenge and leads to high loss of response rates and therapy failure in inflammatory bowel disease (IBD). We aimed to determine the feasibility and pilot effectiveness of a novel, web-based, mobile IFX dosing calculator (mIDC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piester, Travis, Frymoyer, Adam, Christofferson, Megan, Yu, Helen, Bass, Dorsey, Park, K T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	IBD Live
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048868/ https://www.ncbi.nlm.nih.gov/pubmed/29361094 http://dx.doi.org/10.1093/ibd/izx037

Ejemplares similares

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease
por: Anderson, Alyce, et al.
Publicado: (2018)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study
por: Rønnow Sand, Jakob, et al.
Publicado: (2022)

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study
por: Eriksson, Carl, et al.
Publicado: (2018)

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease
por: Darlington, Kimberly, et al.
Publicado: (2023)

Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
por: Lam, Angela Y., et al.
Publicado: (2020)

Barriers to optimizing inflammatory bowel disease care in the United States
por: Spencer, Elizabeth A., et al.
Publicado: (2023)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population‐based study
por: Jayasooriya, Nishani, et al.
Publicado: (2022)

The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases—an international Delphi consensus survey
por: Madsen, Gorm Roager, et al.
Publicado: (2022)

Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden
por: Druvefors, Emma, et al.
Publicado: (2022)

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
por: Kennedy, N A, et al.
Publicado: (2014)

Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2022)

Active tuberculosis in inflammatory bowel disease patients: a case–control study
por: Freitas Cardoso de Azevedo, Matheus, et al.
Publicado: (2023)

Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis
por: Prokopič, Michal, et al.
Publicado: (2023)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method
por: Reinisch, W, et al.
Publicado: (2013)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype
por: Broekman, M. M. T. J., et al.
Publicado: (2017)

The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population‐based, longitudinal study
por: Burgess, Christopher J., et al.
Publicado: (2022)

Harnessing Regulatory T Cells for the Treatment of Inflammatory Bowel Disease
por: Geem, Duke, et al.
Publicado: (2015)

Going Viral: Management of IBD in the Era of the COVID-19 Pandemic
por: Gutin, Liat S., et al.
Publicado: (2020)

Opportunistic Knocks: A Gardener with Ulcerative Colitis and New Pulmonary Nodules
por: Canakis, Andrew, et al.
Publicado: (2023)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases
por: Ochoa-Cortes, Fernando, et al.
Publicado: (2015)

Metagenomic Analysis of Microbiome in Colon Tissue from Subjects with Inflammatory Bowel Diseases Reveals Interplay of Viruses and Bacteria
por: Wang, Weiwei, et al.
Publicado: (2015)

Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study
por: Everhov, Åsa H., et al.
Publicado: (2022)

Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real‐world patient mix
por: Atia, Ohad, et al.
Publicado: (2022)

The disease severity index for inflammatory bowel disease is associated with psychological symptoms and quality of life, and predicts a more complicated disease course
por: Swaminathan, Akhilesh, et al.
Publicado: (2022)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Sugar‐sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants
por: Fu, Tian, et al.
Publicado: (2022)

Inflammatory bowel disease patient‐reported quality assessment should drive service improvement: a national survey of UK IBD units and patients
por: Hawthorne, A. Barney, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhkato2qch1h4qbgi3tfu44prg